New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) |
| |
| Authors: | A Barbeau L Dallaire N T Buu F Veilleux H Boyer L E de Lanney I Irwin E B Langston J W Langston |
| |
| Affiliation: | 1. Clinical Research Institute of Montréal, Montréal, Québec, Canada H2W 1R7;2. Department of Neurology, Stanford University of Medicine, Stanford, CA, USA;3. Santa Clara Valley Medical Center, San Jose, CA 95128, USA;4. Drug Assay Laboratory, Stanford University Hospital, Stanford, CA, USA |
| |
| Abstract: | We report the development of two animal models in amphibians (frogs and salamanders) in whom 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces the behavioral (neurological) and biochemical equivalents of the human disease and, in addition, a measurable modification in at least one form of pigment-bearing cell from the neural crest, the skin melanocyte. We propose that this new approach can become an inexpensive, easily quantifiable model for the study of the effect of MPTP on the central and peripheral nervous systems. We also demonstrate that the toxic effect of MPTP can be completely abolished in vivo by treatment with a monoamine oxidase inhibitor and potentiated by an inhibitor of catechol-O-methyltransferase. MPTP is catabolised by oxidation into toxic metabolites, but 1-methyl-4-phenylpyridinium ion (MPP+), the proposed end-metabolite, is even more toxic than MPTP in this model, possibly through a different mechanism. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
